Abstract
Enoxacin is a fluorinated quinolone with potential clinical use in the treatment of serious infections. Twenty-three patients (age, 19 to 87 years) with different degrees of renal function, including a group undergoing chronic hemodialysis, received enoxacin (400 mg) by intravenous infusion (1 h). Blood samples were collected before infusion; at the end of infusion; and at 5, 10, 20, 30, 45, 60, 90, and 120 min and 3, 4, 6, 12, 18, 24, 48, and 72 h after infusion. Enoxacin and oxoenoxacin concentrations were measured by high-pressure liquid chromatography. Pharmacokinetic parameters (mean +/- standard deviation) were calculated by using a noncompartmental PK model according to creatinine clearances (in milliliters per minute). Total clearance of enoxacin decreased from 4.95 +/- 1.16 ml/min per kg in the group with normal creatinine clearance to 0.76 +/- 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance, less than 15 ml/min), whereas the elimination half-life increased from 4.5 +/- 1.0 to 20 +/- 5 h, respectively. The elimination of oxoenoxacin (the main metabolite of enoxacin) in urine was markedly decreased when creatinine clearance was less than 15 ml/min. Hemodialysis removed an insignificant amount of enoxacin and oxoenoxacin. These data indicate that as creatinine clearance falls below 30 ml/min, the daily enoxacin dose should be reduced by half. During prolonged administration of enoxacin to patients with creatinine clearances of less than 30 ml/min, the accumulation of oxoenoxacin might lead to unexpected side effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bury R. W., Becker G. J., Kincaid-Smith P. S., Moulds R. F., Whitworth J. A. Elimination of enoxacin in renal disease. Clin Pharmacol Ther. 1987 Apr;41(4):434–438. doi: 10.1038/clpt.1987.53. [DOI] [PubMed] [Google Scholar]
- Harper J. F. Peritz' F test: basic program of a robust multiple comparison test for statistical analysis of all differences among group means. Comput Biol Med. 1984;14(4):437–445. doi: 10.1016/0010-4825(84)90044-1. [DOI] [PubMed] [Google Scholar]
- Houston J. B. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):521–552. doi: 10.1016/0163-7258(81)90056-5. [DOI] [PubMed] [Google Scholar]
- Nix D. E., Schultz R. W., Frost R. W., Sedman A. J., Thomas D. J., Kinkel A. W., Schentag J. J. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):87–95. doi: 10.1093/jac/21.suppl_b.87. [DOI] [PubMed] [Google Scholar]
- Van der Auwera P. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin. Infection. 1986 May-Jun;14(3):142–144. doi: 10.1007/BF01643481. [DOI] [PubMed] [Google Scholar]
- Vree T. B., Baars A. M., Wijnands W. J. High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva. J Chromatogr. 1985 Oct 11;343(2):449–454. doi: 10.1016/s0378-4347(00)84618-6. [DOI] [PubMed] [Google Scholar]
- van der Auwera P., de Moor G., Lacroix G., Mambour A., Rossion N., Schuyteneer F. In vitro activity of enoxacin compared with norfloxacin and amikacin. Eur J Clin Microbiol. 1985 Feb;4(1):55–58. doi: 10.1007/BF02148662. [DOI] [PubMed] [Google Scholar]